Results 201 to 210 of about 50,334 (225)

Glucocorticoids for Thyroid Eye Disease

International Ophthalmology Clinics, 2021
Peter J, Dolman, Magdalena A, Wirth
openaire   +2 more sources

Thyroid Eye Disease

2019
Thyroid eye disease is the most common cause of orbital disease encountered in clinical practice. It most often occurs in patients with Graves disease, but can also occur in the absence of thyroid dysfunction. In this chapter, we begin by reviewing the clinical features and natural history of thyroid eye disease.
Matthew J. Thurtell, Robert L. Tomsak
openaire   +1 more source

Management of Thyroid Eye Disease: A Consensus Statement by the American Thyroid Association and the European Thyroid Association

Thyroid, 2022
Henry B Burch, Petros Perros, Tomasz Bednarczuk   +2 more
exaly  

Teprotumumab for chronic thyroid eye disease

Orbit, 2022
Daniel J Ozzello, Liane O Dallalzadeh
exaly  

Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment

Ophthalmology, 2022
George J Kahaly, Shoaib Ugradar, Heike Elflein   +2 more
exaly  

Teprotumumab for Thyroid Eye Disease

International Ophthalmology Clinics, 2020
Christopher J, Hwang, Kian, Eftekhari
openaire   +2 more sources

The Role of Thyroid Antibodies in Thyroid Eye Disease

International Ophthalmology Clinics, 2023
Rachel Shemesh, Guy J. Ben Simon, Ofira Zloto   +2 more
openaire   +2 more sources

Teprotumumab for the Treatment of Active Thyroid Eye Disease

New England Journal of Medicine, 2020
George J Kahaly, Amy Patel, Claudio Marcocci   +2 more
exaly  

Updates on the understanding and management of thyroid eye disease

Therapeutic Advances in Ophthalmology, 2021
Clara J Men, Andrea L Kössler, Sara T WESTER   +2 more
exaly  

2022 Update on Clinical Management of Graves Disease and Thyroid Eye Disease

Endocrinology and Metabolism Clinics of North America, 2022
Thanh D Hoang, Henry B Burch
exaly